Pacific Biosciences of California, Inc. (PACB) Posts Q3 EPS Loss of $0.54, Sales Top Expectations

Pacific Biosciences of California, Inc. (NASDAQ: PACB) reported Q3 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $10.52 million versus the consensus estimate of $9.73 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Smith & Wesson Brands (SWBI) Tops Q4 EPS by 15c